CO-NEWMONT-CORPORATION
8.2.2024 14:31:30 CET | Business Wire | Press release
Newmont Corporation (NYSE: NEM, TSX: NGT, ASX: NEM, PNGX: NEM) and Project C.U.R.E. announce a five-year agreement to deliver medical supplies and life-saving training for healthcare providers in developing countries and communities near Newmont mining operations. Under the agreement, Newmont commits to an annual contribution of $200,000 over the next five years, totaling $1 million.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240208935869/en/
Newmont and Project C.U.R.E.’s partnership has created a positive economic ripple effect across 36 countries. (Graphic: Business Wire)
“Creating a positive impact on more than 10 million people globally, through our partnership with Project C.U.R.E. is something we are incredibly proud of,” said Suzy Retallack, Newmont’s Chief Safety and Sustainability Officer. “For nearly two decades, our partnership has helped deliver support to host communities near our operations and around the world. We look forward to continuing to leverage our combined global reach to make a strong impact where it is needed most.”
Since 2005, Newmont has partnered with Project C.U.R.E. to distribute more than $42 million worth of much-needed medical supplies and equipment through multiple sponsorship initiatives. Highlights of the partnership include:
- Funding 108 shipping containers of medical equipment to 36 countries.
- Impacting more than two million patients through Newmont’s support of the C.U.R.E. Cargo program.
- Training more than 440 medical professionals, through the C.U.R.E. College program, in resource-limited environments to reduce neonatal and maternity morbidity and mortality.
- Contributing $5 million to support humanitarian efforts relating to the ongoing war in Ukraine, providing direct support to Project C.U.R.E., the American Red Cross and International Medical Corps.
- Delivering 164 C.U.R.E. kits – suitcase-sized, pre-packed kits of essential medical supplies – through Newmont employees to healthcare facilities in Ethiopia, Ghana, Indonesia, Mexico, Nicaragua, Peru and Suriname.
“We are proud of our partnership with the team at Newmont. For nearly two decades, we have worked together to save lives and strengthen the healthcare infrastructure for millions of people,” said Dr. Douglas Jackson, President and CEO of Project C.U.R.E. “In countries like Ghana and Suriname and now Mexico, Guatemala and others, we have established a figurative gold standard for corporate social responsibility and making our communities healthier, happier and more hopeful.”
Also, as part of Newmont’s partnership, employees around the world participate in myriad volunteer opportunities – logging hundreds of hours of time and service helping sort supplies at the Project C.U.R.E. warehouse, packing and unloading containers, and carrying medical kits to communities near Newmont operations.
About Project C.U.R.E.
Established in a garage in Evergreen, Colorado in 1987, Project C.U.R.E. has grown to be the world’s largest distributor of donated medical supplies and equipment to people living in developing countries. Since 2000, Project C.U.R.E. has delivered more than $1 billion of medical relief to save the lives of people facing poverty, disasters and violence. Project C.U.R.E. has worked in 138 countries, establishing an incredible footprint of medical relief around the world.
As a registered 501(c)(3), Project C.U.R.E.’s goal is to bridge the staggering health resource gaps in the developing world by empowering doctors and nurses with the tools they need—medical supplies and equipment—to treat disease, deliver vaccines, perform life-changing surgeries, and ensure safe childbirth. On average, Project C.U.R.E. delivers five forty-foot containers of donated medical relief each week.
About Newmont
Newmont is the world’s leading gold company and a producer of copper, zinc, lead, and silver. The company’s world-class portfolio of assets, prospects and talent is anchored in favorable mining jurisdictions in Africa, Australia, Latin America & Caribbean, North America, and Papua New Guinea. Newmont is the only gold producer listed in the S&P 500 Index and is widely recognized for its principled environmental, social, and governance practices. Newmont is an industry leader in value creation, supported by robust safety standards, superior execution, and technical expertise. Founded in 1921, the company and has been publicly traded since 1925.
At Newmont, our purpose is to create value and improve lives through sustainable and responsible mining. To learn more about Newmont’s sustainability strategy and initiatives, go to www.newmont.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240208935869/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 21:50:00 CET | Press release
Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme
Andersen Consulting styrker sine kompetencer i samarbejde med Acumen Learning12.3.2026 21:36:00 CET | Pressemeddelelse
Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Acumen Learning, en amerikansk virksomhed, der specialiserer sig i træning i forretnings- og økonomiforståelse med henblik på lederudvikling og salgsresultater. Acumen Learning blev stiftet i 2002 og samarbejder med Fortune 500-virksomheder for en bedre finansiel forståelse, strategisk tænkning og beslutningstagning på alle niveauer. Med udgangspunkt i principperne fra deres bestsellerbøger "Seeing the Big Picture" og "Business Acumen for Sales Success" klæder deres programmer ledere og teams på til at afstemme beslutninger med virksomhedsstrategier, fremme resultater og styrke kunderelationer. Acumen Learning er målrettet brancher som sundhedssektoren, energi og teknologi og giver fagfolk mulighed for at omsætte forretningsviden til håndgribelige resultater. "Hos Acumen Learning er vores mission at styrke det enkelte menneske ved at skabe forretningskyndige fagfolk, der gør en forskel i deres karrierer," udtalte K
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release
All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
